{"id":"NCT04650087","sponsor":"Thomas L. Ortel","briefTitle":"COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis","officialTitle":"COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-15","primaryCompletion":"2022-07-24","completion":"2022-09-23","firstPosted":"2020-12-02","resultsPosted":"2025-02-25","lastUpdate":"2025-02-25"},"enrollment":1291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Covid19"],"interventions":[{"type":"DRUG","name":"Apixaban 2.5 MG","otherNames":["Eliquis"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Apixaban","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge","primaryOutcome":{"measure":"Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial Thromboembolism, and All-cause Mortality as Measured by Hospital Records.","timeFrame":"30 days after hospital discharge","effectByArm":[{"arm":"Placebo","deltaMin":2.31,"sd":null},{"arm":"Apixaban","deltaMin":2.13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":11},"locations":{"siteCount":121,"countries":["United States"]},"refs":{"pmids":["37591523","36940444"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":610},"commonTop":["WORSENING COVID-19 PNEUMONIA","FALL","WORSENING PNEUMONIA","CHEST PAIN","ELEVATED D-DIMER"]}}